- Home
- ITOS
as 03-13-2025 4:00pm EST
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | WATERTOWN |
| Market Cap: | 270.7M | IPO Year: | 2020 |
| Target Price: | $26.00 | AVG Volume (30 days): | 334.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.32 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.67 - $18.75 | Next Earning Date: | 03-05-2025 |
| Revenue: | $35,000,000 | Revenue Growth: | 177.89% |
| Revenue Growth (this year): | -80.49% | Revenue Growth (next year): | 121.70% |
Latest iTeos Therapeutics Inc. News
ITOS Breaking Stock News: Dive into ITOS Ticker-Specific Updates for Smart Investing
Simply Wall St.
8 days ago
iTeos Therapeutics Full Year 2024 Earnings: In Line With Expectations
GlobeNewswire
9 days ago
iTeos Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
Simply Wall St.
a month ago
We Think iTeos Therapeutics (NASDAQ:ITOS) Needs To Drive Business Growth Carefully
Zacks
2 months ago
All You Need to Know About iTeos Therapeutics (ITOS) Rating Upgrade to Buy
GlobeNewswire
2 months ago
iTeos Announces 2025 Strategic Priorities and Anticipated Milestones
GlobeNewswire
2 months ago
iTeos to Present at the 43rd Annual J.P. Morgan Healthcare Conference
TipRanks
3 months ago
iTeos Therapeutics price target lowered to $19 from $31 at Wells Fargo
Clinical Trials Arena
3 months ago
Inupadenant “deprioritised” by iTeos in favour of pipeline TIGIT therapy
Compare ITOS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ITOS iTeos Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.